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There is a growing interest in developing effective tools to better probe the central nervous system (CNS), to under-
stand how it works and to treat neural diseases, injuries and cancer. The intrinsic complexity of the CNS has made this 
a challenging task for decades. Yet, with the extraordinary recent advances in nanotechnology and nanoscience, there 
is a general consensus on the immense value and potential of nanoscale tools for engineering neural systems. In this 
review, an overview of specialized nanomaterials which have proven to be the most effective tools in neuroscience is 
provided. After a brief background on the prominent challenges in the field, a variety of organic and inorganic-based 
nanomaterials are described, with particular emphasis on the distinctive properties that make them versatile and 
highly suitable in the context of the CNS. Building on this robust nano-inspired foundation, the rational design and 
application of nanomaterials can enable the generation of new methodologies to greatly advance the neuroscience 
frontier.
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1  Background
The fields of biology and medicine have heavily relied 
on advances in technology to better understand how 
the human body works. These advances range from the 
creation of simple tools to conduct surgery (e.g. scalpel), 
devices to measure physiological levels (e.g. electrocar-
diograph) and instrumentation to image the body in real 
time (e.g. fMRI). Besides studying the human physiol-
ogy, these types of technological advances have further 
enhanced our capabilities to diagnose, prevent and even 
treat medical ailments such as disease, cancer and trau-
matic injuries. In general, the continual development of 
precision tools has enabled scientists and clinicians to 
acquire a remarkable breadth of knowledge about bio-
logical systems.
Among other disciplines, the field of neuroscience has 
greatly benefited from such advances. Neuroscientists 
have long strived to acquire a complete understanding 
of how the nervous system works. Early work involved 
investigating the bulk anatomical makeup of the brain, 
primarily through dissecting human cadavers. Taking 
the human brain as an example, it is organized into dis-
tinct lobes within the centimeter range (Fig. 1). The lobes 
were recognized to correspond to specific physiological 
functions, whether it be processing sensations of touch 
(parietal lobe) or controlling body movement (frontal 
lobe). Thereafter, the discovery of the role of electric-
ity in nerve signaling, along with the development of 
microscopy, allowed scientists to go even deeper to the 
micrometer scale of neurons and glia cells. Millions of 
neurons in the distinct regions of the brain, are organ-
ized into ensembles or circuits, which serve to process 
and carry information throughout the nervous system. 
Going even deeper to the nanometer scale, the distinct 
neural cells are composed of numerous biomolecules and 
receptors on the surface membrane, which enable multi-
directional interactions with the surrounding microenvi-
ronment. There is growing interest in the miniaturization 
of tools to better control and understand neural systems 
at this fundamental scale [1]. Biological systems function 
with extraordinary fidelity at the molecular level, which 
permits robust structure and function at the cellular, 
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tissue and organ level. The ability to probe systems like 
the nervous system at the fundamental resolution that 
they have naturally evolved to function is revolutionary. 
Nanotechnology has enabled the design of materials and 
devices to do just that. It has enhanced our understand-
ing of how biological systems work at the nanoscale, and 
further allowed the development of nanoscale tools to 
improve the quality of life after disease or injury [2]. The 
integration of engineered materials with intact biologi-
cal systems has proven to be highly transformative and 
is possible due to the growing understanding of nanosci-
ence and nanotechnology.
To this end, nanoscale materials hold immense poten-
tial for engineering neural systems. The ability to pre-
cisely tailor the properties of nanomaterials permits 
scientists and clinicians to effectively employ them for a 
wide variety of applications. In this review, we will first 
explore the current challenges and existing approaches 
in the field of neuroscience. We will then see how nano-
materials can be utilized to address these challenges, 
with a focus on the distinctive properties that make them 
highly suitable tools for advancing neuroscience research 
(Fig. 1).
2  Current challenges and approaches 
in neuroscience
The central nervous system (CNS) consists of the brain 
and the spinal cord. The brain primarily coordinates and 
processes higher-level functions (e.g. sensory process-
ing, cognition, motor movements, etc.), while the spinal 
cord serves as a medium of communication between the 
brain and the periphery. The CNS is further composed 
Fig. 1 The nanomaterial toolkit for neuroengineering. Schematic depicting the anatomical organization of the brain at different size scales (top) 
and the different types of inorganic and organic nanomaterials which have been utilized for neuroscience
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of two key cell types: neurons and glia. Neurons serve 
to process changes in the environment, communicate 
the changes throughout the system and direct the body’s 
response to such changes. Glia are the supportive and 
most abundant cells of the nervous system which help 
support neighboring neurons and maintain homeosta-
sis. The intricate network of billions of these neural cells, 
presumably organized in defined arrangements to impart 
specific neural activity, gives rise to thoughts, feelings, 
memories and life as we know it. In this section, we will 
look at three key areas of active CNS research: (a) neuro-
regenerative therapies, (b) delivery of therapeutics, and 
(c) neuromodulation.
2.1  Neuro‑regenerative therapies
The CNS is very sensitive to damage, including infection, 
hypoxia, stroke, neurodegenerative diseases, and injury. 
The inevitable loss of neural cells makes this particu-
larly devastating, since it leads to debilitating motor and 
cognitive impairment. For example, Parkinson’s disease 
(PD) results in the gradual loss of midbrain neurons in 
the substantia nigra which synthesize the neurotrans-
mitter dopamine (DA), leading to rigidity and tremors 
[3]. Like neurodegenerative diseases, traumatic injuries 
can cause the loss of neural cells, in addition to complex 
microenvironments as the injury progresses from acute 
to chronic stages [4]. If kept untreated, a series of dam-
aging conditions continue to accumulate, resulting in 
continued degeneration and dysfunction [5]. Due to the 
limited regenerative capabilities of the CNS, the loss of 
nervous tissue is extremely detrimental. To this end, cel-
lular-based therapies have emerged as a promising route 
of therapy for CNS-related diseases and injuries [6]. The 
rationale is simple: replace the lost cells with new cells, 
in order to restore function. Cell transplantation started 
with clinical trials in patients with PD, in which trans-
plantation of human fetal mesencephalic tissue rich in 
dopaminergic neurons was found to normalize dopamine 
release and reverse impairment in cortical activation [7, 
8]. However, such an approach relies on the availabil-
ity of donor tissue, making it an impractical long-term 
solution.
In this context, stem cell-based therapies have gained 
tremendous attention for neural disorders [9]. Stem 
cells are particularly suitable since they have the innate 
capability to self-renew, serving as a renewable source 
of transplantable cells that can be routinely expanded. 
At the same time, stem cells can differentiate into vari-
ous cellular lineages, allowing for the generation of spe-
cific neural cell types of interest. Various types of stem 
cells, including embryonic stem cells (ESCs), induced 
pluripotent stem cells (iPSCs), fetal neural stem cells 
and mesenchymal stem cells (MSCs), have proven to be 
therapeutically beneficial after transplanting into dam-
aged neural systems [10–12]. While cell transplantation 
initially started as an approach for cell replacement, the 
transplanted stem cells have been observed in recent 
years to imbue a number of favorable therapeutic effects 
in the CNS recovery process. This includes a decrease in 
inflammation, neuro-protection, remyelination, produc-
tion of neurotrophic factors to enhance axonal regen-
eration and the enhancement of endogenous recovery 
processes [13].
Nevertheless, an active area of current research lies in 
achieving reproducible control of stem cell differentia-
tion towards a pure, defined neural cell populations. The 
uncontrolled stem cell growth or differentiation after 
transplantation (e.g. teratoma formation from pluripo-
tent cells [14]) is clearly unacceptable for clinical appli-
cations. Moreover, in vitro differentiation protocols tend 
to be fairly lengthy and complex; the general biologist’s 
approach tends to require supplementing a number of 
chemical compounds, biological factors or viral gene vec-
tors, which can lead to high variability between experi-
ments. Another common problem is the limited survival 
of transplanted cells and poor interaction with host tis-
sue. For this reason, long-term viability and integration 
are critical factors to consider when it comes to re-estab-
lishing the damaged neuronal circuitry [13]. At the same 
time, the in  vivo CNS microenvironment can be highly 
heterogeneous, with major fluctuations at the molecular 
and cellular level especially in the damaged site. In turn, 
achieving spatiotemporal control of stem cell behavior 
and differentiation after transplantation is quite challeng-
ing [15]. Engineering how the cell interacts with the sur-
rounding environment is therefore critical when it comes 
to advancing stem cell-based neuro-regenerative thera-
pies [16].
2.2  Delivery of therapeutics to the CNS
Pharmacological approaches have been widely explored 
for the delivery of therapeutics to the CNS [17]. Thera-
peutic agents for CNS delivery result from screening 
the fundamental mechanisms of action in normal neu-
ral tissue versus diseased/damaged tissue. In this regard, 
therapeutics which are valuable and effective against 
neural disorders can come in many different forms. For 
instance, restoring the sufficient levels of the neuro-
transmitter dopamine has been reported to be a viable 
treatment option for patients with PD, leading to the 
use of dopamine precursors like levodopa or dopamine 
agonists [18]. On the other hand, anticancer drugs are 
essential for treating malignant brain tumors like glio-
blastoma multiforme (GBM), one of the most aggres-
sive forms of brain cancer [19]. A number of drugs have 
been designed to target different molecular pathways, 
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including paclitaxel and temozolomide [20]. Biopharma-
ceutics have also become attractive for CNS therapies. 
These include peptides, recombinant proteins, enzymes, 
monoclonal antibodies, and gene vectors. Compared to 
small molecule drugs, this class of therapeutics tends to 
have higher specificity and potency [21]. For instance, 
genomic sequencing and bioinformatics approaches have 
identified therapeutic targets for GBM that can be tar-
geted with viral vectors and microRNAs [22]. In another 
example, in  vivo administration of antibody inhibitors 
targeting β-secretase and α-synuclein were found to 
reduce amyloid-β concentrations [23] and α-synuclein 
aggregates [24], respectively, for treating dementia.
While multitudes of therapeutics exist for treatment, 
delivery to the CNS has proven to be challenging. Intrac-
erebroventricular injection is one direct delivery option, 
wherein therapeutics are injected directly into the cer-
ebral lateral ventricles [25]. However, such a strategy is 
highly invasive and not a feasible option for therapies 
requiring frequent injections. Intrathecal administra-
tion via cerebrospinal routes is also popular and gener-
ally favorable, but the restricted diffusion in the brain 
compared to the blood is a limiting factor [21]. These 
challenges arise from the fact that the CNS is highly-
protected and dynamically-regulated by key physical bar-
riers, which prevent the invasion of foreign or unwanted 
substances. While favorable for maintaining homeo-
stasis, it is a critical obstacle for the systemic delivery 
of therapeutic agents. The blood–brain barrier (BBB) is 
the primary barrier protecting the CNS, consisting of a 
layered structure composed of endothelial cells, the cap-
illary basement membrane, pericytes and astrocyte foot 
processes [26]. The tight junctions formed between the 
endothelial cells permits the free diffusion of small mol-
ecules, such as oxygen, carbon dioxide and water, but 
highly limits the movement of large molecules including 
most therapeutics [27].
Even though systemic delivery is limited by the BBB, 
targeted therapies have been developed to enhance the 
permeability across the BBB by: modifications of the 
drug, temporary disruption of the BBB using chemical 
or physical perturbation, catheter-based interstitial deliv-
ery or drug-eluting reservoir systems [28]. Depending on 
the approach, there are multiple design considerations 
to take into account. The first is the type of therapeutic 
that is to be delivered. Given that different compounds 
have varying chemical, physical and biological proper-
ties (e.g. small molecules versus antibody versus RNA 
molecule), the stability and formulation must be main-
tained for maximum efficacy. Second, sufficient dosing 
must be achieved to stay within the therapeutic window. 
The amount of drug administered versus the actual drug 
that reaches the target can significantly differ due to 
fluctuations in pharmacokinetics. This may thus require 
higher effective doses, which can be lethal, expensive, 
and compromise patient compliance. Balancing these 
considerations based on the neurological disorder to be 
treated is therefore essential for enhancing therapeutic 
delivery to the CNS.
2.3  Neuromodulation
Mapping the neural circuitry of the brain is currently 
a major initiative for neuroscientists worldwide [29]. 
Determining the specific organization of billions of neu-
rons, interconnected via trillions of synapses, is funda-
mental to unlocking how the CNS processes information 
to coordinate neural activity, cognition and behavior [30]. 
In this regard, there is a general consensus on the need 
for tools to better interface with the nervous system to 
enable the measurement and manipulation of neural 
signaling.
Electrodes are commonly used to record and stimulate 
neural activity. The most basic system is an electrolyte-
filled micropipette, which is still employed for in  vitro 
electrophysiology experiments to measure changes in 
current and/or potential of neurons [31]. By further 
modifying the physical dimensions, electrodes have been 
placed into mammalian brains for local neural stimu-
lation and recording as well. One such example is deep 
brain stimulation, in which electrodes are implanted and 
stimulated near the internal globus pallidus and sub-
thalamic nucleus to treat PD patients [32]. In order to 
acquire multipoint readings, microfabrication techniques 
and MicroElectroMechanical Systems (MEMS) have also 
been widely used to generate micron-scale multielec-
trode arrays [33]. For electrode compositions in general, 
a number of different metals have been explored, includ-
ing gold, platinum, steel and iridium oxide [34]. However, 
metallic electrodes tend to be mechanically hard (50–
500  GPa) compared to soft nervous tissue (0.1–1  kPa), 
which causes neural damage and incurs an inflammatory 
response after insertion [35]. Yet, electrodes must also be 
brought in close proximity to the target region for both 
effective stimulation and measurement. At the same 
time, long-term implantation further causes a chronic 
inflammatory response, leading to gliosis near the surface 
of the electrode and thus reducing signal transduction 
due to the increase in the impedance [36].
A recent technology that has significantly transformed 
neuromodulation approaches is optogenetics. Optoge-
netics involves genetically engineering cells to express 
photosensitive proteins, which would in turn alter their 
membrane potential or other cellular properties upon 
illumination. The core premise of this new sub-field of 
neuroscience lies in the selective expression of microbial 
opsin genes in targeted neural populations. For example, 
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the expression of visible light-activated cation chan-
nels from algal species, such as the 470-nm blue-light 
responsive channelrhodopsin-2 from Chlamydomonas 
reinhardtii (ChR2) or the 535-nm green-light responsive 
channelrhodopsin-1 from Volvox carteri (VChR1), into 
mammalian neurons were found to transduce trains of 
millisecond-duration light flashes into time-locked depo-
larizations [37]. On the other hand, chloride-pumping 
halorhodopsin from Natronomonas pharaonis (NpHR) 
can hyperpolarize and thus inhibit neuronal firing using 
yellow-light (589 nm) [38]. Molecular engineering tech-
niques to modify these microbial proteins and encode 
them in viral vectors has allowed for the introduction 
of these opsin genes into mammalian cells, with the first 
in  vitro demonstration using mammalian neurons in 
2005 [39]. By 2007, the first in vivo demonstration which 
linked optically-manipulated neural activity with spe-
cific behavioral changes in freely-moving mammals was 
reported [40]. By combining the spatiotemporal resolu-
tion of optical hardware with the genetic manipulation of 
specific cell types, optogenetics has allowed for the pre-
cise control of neural activity in select regions of the brain 
[41]. In other words, exposure of genetically-manipulated 
neuronal cells to light has facilitated the ability to modu-
late neural activity at a timescale relevant to brain func-
tion. Over the last decade, optogenetic techniques have 
elucidated neuronal circuits of numerous neural-related 
states and disorders including fear and anxiety, addiction, 
depression, reward-seeking, schizophrenia and PD [42]. 
While optogenetics is continuing to enable novel studies 
that were previously impossible, a number of fundamen-
tal limitations exist, including lack of deep tissue penetra-
tion using conventional visible light sources, the need for 
invasive surgeries to deliver light, and difficulties in tar-
geting deeper brain regions [43]. A completely non-inva-
sive approach for neural modulation would be ideal, but 
it may prove to be difficult due the lack of precise control 
in mapping or stimulating specific regions of the brain 
without intervention.
Regardless of the approach employed to modulate neu-
ral activity, a clear consideration for future development 
is to reduce invasiveness while achieving maximal qual-
ity of signal recording or stimulation. The key will be to 
design materials that offer optimal interfacing with intact 
nervous tissue, both in regard to structural (i.e. mechani-
cal) and surface (i.e. chemical, physical) properties.
3  Nanomaterials for neuroengineering
Nanomaterials have a number of unique properties that 
make them attractive for addressing the abovemen-
tioned challenges. For instance, the small size (below 1 
micron) enables facile delivery throughout the body and 
into cells by crossing the plasma membrane [44]. While 
different cell types may have a different composition of 
lipids and proteins in the plasma membrane, nanoma-
terials cross the plasma membrane and are internalized 
in a size-dependent manner via endocytosis pathways, 
such as clathrin-mediated endocytosis, caveolae-medi-
ated endocytosis, or phagocytosis [45]. Moreover, the 
surface chemistry of the nanomaterial also plays a defin-
ing role, wherein it can be adjusted to selectively bind 
biomolecules found on the cell membrane, in specific 
normal/diseased tissues, or in bodily fluids (e.g. blood, 
interstitial fluids, etc.). This can be achieved by conju-
gating cell-specific targeting ligands or antibodies to the 
surface. As a result, nanomaterials can be preferentially 
targeted to specific tissues (e.g. cancerous tissue) upon 
injection into the blood stream. At the same time, the 
nanomaterial surface can be chemically-functionalized 
(e.g. PEGylation) to improve circulation time in the body 
and evade clearance by the liver or kidney [46]. In addi-
tion, nanomaterials with a variety of different composi-
tions, both inorganic and organic, can be synthesized. 
This is especially advantageous since different composi-
tions impart specific physicochemical, thermal, electrical, 
magnetic, mechanical, and/or optical properties of the 
nanomaterial. In this section, we will explore the vari-
ous types of inorganic and organic nanomaterials which 
have been used for to address the prominent challenges 
in neuroscience.
3.1  Inorganic nanomaterials
The following inorganic nanomaterials will be described 
in this section: metallic nanoparticles, silica nanoparti-
cles, magnetic nanoparticles, quantum dots and upcon-
version nanoparticles.
3.1.1  Metallic nanoparticles
Metallic nanoparticles are useful in medicine due their 
unique surface properties. Exposure to an oscillating 
electromagnetic field of light causes the free electrons 
of the metallic nanoparticle to undergo a collective 
coherent oscillation, termed localized surface plas-
mon resonance (LSPR) oscillation [47]. In turn, there 
is strong enhancement of the scattering and absorption 
cross-section at the LSPR frequency, which is advanta-
geous since it lies in the visible spectra for noble metals 
such as gold (Au) and silver (Ag) [47]. This surface-
based phenomenon imparts a size- and shape-depend-
ent optical modality to AuNPs and AgNPs, which can 
be exploited for bio-imaging, sensing and labelling [48]. 
Moreover, metallic particles such as AuNPs are well-
established to be biologically inert and easily amendable 
to functional modification, allowing for the conjugation 
of biomolecules such as antibodies, proteins and oligo-
nucleotides [49].
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These properties have been exploited for numerous 
neural applications. In one study, 10-nm AuNPs were 
employed to dissolve amyloid beta (Aβ) aggregates linked 
with Alzheimer’s disease (AD) [50]. A specialized PEP 
peptide (sequence H-Leu-Pro-Phe-Phe-Asp-NH2) was 
then attached to the AuNP, which can facilitate selec-
tive binding to Aβ aggregates. Thereafter, exposure to 
a low gigahertz electromagnetic field prompted local 
heat dissipation from the AuNPs, which then dissolved 
the aggregates. In another study, AgNPs were employed 
to study the interaction of amyloid β-derived diffusible 
ligand (ADDL) and the anti-ADDL antibody for an opti-
cal biosensor to diagnose AD (Fig. 2a) [51].
In order to make effective electrodes, AuNPs assembled 
using a layer-by-layer approach to form electrodes which 
were shown to yield low impedance and high charge stor-
age capacity (Fig.  2b) [52]. This initial demonstration 
of using AuNPs for neural interfaces showed improve-
ments in the signal-to-noise ratio, long-term recording, 
and delivery of a higher charge per area of electrode to 
the surrounding tissue. In recent work, AuNPs have been 
used to further target neurons for neuromodulation [53]. 
Spherical 20-nm AuNPs were attached to high-avidity 
ligands targeting different membrane proteins of dorsal 
root ganglion (DRG) neurons (Fig. 2c). After binding to 
the neuron, the particles transduce millisecond pulses of 
light into heat, which sufficiently altered the membrane 
capacitance to elicit action potentials. This AuNP-based 
strategy worked well for all tested ligands to induce 
selective stimulation, providing an alternative to optoge-
netic techniques. These diverse studies highlight the 
potential of metallic nanoparticles for a diverse array of 
neuroapplications.
3.1.2  Silica nanoparticles
Silica is categorizes as a “Generally Recognized As Safe” 
material by the FDA, and is widely used for food addi-
tives and cosmetics [54]. Besides the favorable biocom-
patibility features, nanoparticles composed of silica are 
promising due to their robust structural stability and high 
drug loading [54]. It is also a highly transparent, dielectric 
material that does not absorb light nor conduct electrons 
Fig. 2 Gold nanoparticles (AuNPs). a Nanoscale AuNP-based optical biosensors for monitoring the interaction between amyloid-β derived diffus-
ible ligands and specific antibodies. Reproduced with permission from Ref. [51]. Copyright (2005) American Chemical Society. b Layer-by-layer coat-
ing of AuNPs on electrodes for improved interfacial impedance and charge storage capacity. Reproduced with permission from Ref. [52]. Copyright 
(2012) American Chemical Society. c Schematic (left) for AuNPs (red) perfused over a patch-clamped DRG neuron through one side, then washed 
with fresh buffer to remove the NPs. Representative traces (right) of current-clamped DRG cells firing action potentials in response to current injec-
tions (blue bars) and 532-nm green light pulses (green pulse). Cells are responsive to current injection, and a bolus of AuNPs sensitized the cells to 
light stimulation. Reprinted from Ref. [53]. Copyright (2015), with permission from Elsevier
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[55]. As an inert host, silica can further serve as a matrix 
for the construction of well-ordered particles capable of 
containing small molecule drugs and biomolecules.
Silica NPs are generally categorized as nonporous or 
mesoporous. While both are derived from an amor-
phous silica structure, mesoporous silica NPs have a 
porous structure (2–50  nm pore size), which can allow 
for enhanced drug loading [56]. Mesoporous silica can 
therefore deliver a payload (e.g. drugs, proteins, genes) 
by entrapping it within the pores and releasing it through 
passive diffusion or the controlled opening of a chemi-
cal/biological cap covering the pores (Fig.  3a) [57]. For 
instance, a recent study released nerve growth factors 
(NGF) using mesoporous silica nanoparticles, which not 
only prevented clearance and degradation of NGF, but 
improved delivery to promote nerve cell proliferation and 
neurite outgrowth [58]. Others have loaded agents, like 
111 In radiolabeling, to enable multimodal in vivo imaging 
and tracking [59].
Recent studies have explored the response of differ-
ent neural tissue-type cells, like neural stem cells, neu-
rons, astrocytes and microglia, to silica NP treatment in 
order to assess optimal surface modifications that ensure 
minimal cytotoxicity [60]. These silica-cell interactions 
have further been exploited to provide nanotopographi-
cal features on interfacial surfaces. For instance, a self-
assembled silica nanoparticle monolayer was employed 
to deliver negatively-charged RNA-based molecules (e.g. 
siRNA, miRNA) into neural stem cells to control neu-
ronal differentiation (Fig.  3b) [61]. This substrate-medi-
ated delivery for the nanoparticle film was non-toxic, 
highly effective, and achieved in the absence of cationic 
polymers.
The biocompatibility of silica has made it attractive 
for brain delivery. It is often used as an inert shell layer 
to coat other types of nanoparticles, as seen with mag-
netic nanoparticles delivered to track neural progeni-
tor cells in ischemic mice [62]. Among the multitude of 
Fig. 3 Silica nanoparticles (SiNPs). a Transmission electron microscopy images of mesoporous silica nanoparticles, acquired parallel (left) or perpen-
dicular (right) to the long axis of the mesoporous channels. Reprinted from Ref. [57]. Copyright (2008), with permission from Elsevier. b Scanning 
electron microscopy image of neural stem cells (orange) grown on SiNP films (blue). Reproduced with permission from Ref. [61]. Copyright 2013 
Nature Publishing Group. c Stereotaxic injection of SiNP-conjugated EGFP gene plasmids into mice brain. Left side image shows cells staining for 
EGFP in the substantia nigra. Right side image shows co-staining for transfected EGFP (green) and tyrosine hydrolase-positive dopaminergic neurons 
(red). Reproduced with permission from Ref. [63]. Copyright 2005 National Academy of Sciences, USA
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reports utilizing silica NPs for delivery to cells, Bharali 
et  al. provided the first demonstration for in vivo deliv-
ery using silica NPs as a nonviral vector [63]. Stable aque-
ous dispersions of organically-modified silica NPs, bound 
with DNA-encoding EGFP, were prepared. Interestingly, 
this report described stereotaxic injection of the com-
plexes into the mouse ventral midbrain and lateral ven-
tricle. In addition to exhibiting no toxicity four weeks 
after transfection, the green fluorescence was visualized 
in the substantia nigra along with localization in tyros-
ine hydroxylase (TH)-positive dopaminergic neurons 
(Fig.  3c). This initial study gave promise for using silica 
NPs for in  vivo delivery and brain-targeting therapies. 
These features of silica NPs make them an attractive 
option for future neural studies.
3.1.3  Magnetic nanoparticles
Magnetic nanoparticles (MNPs) are attractive due to 
the superior contrast enhancement they offer for in vivo 
imaging. Magnetic resonance imaging (MRI) is one 
of the most widely used medical imaging techniques, 
which relies on measuring the relaxation times of excit-
able hydrogens in the tissue to acquire high-resolution 
images. Since such intrinsic differences tend to be insuf-
ficient for obtaining a detectable signal, contrast agents 
bearing paramagnetic or superparamagnetic properties 
are often used. MNPs, such as iron oxide-based parti-
cles (Fe2O3 and Fe3O4), are excellent MRI contrast agents 
for improved sensitivity in T-2-weighted imaging [64]. 
MNPs composed of iron oxide are clinically approved as 
MRI contrast agents, in which Feridex and Resovist well-
known commercial products [65].
MNPs tend to be most effective when the size is typi-
cally around 10–20  nm [66]. Over the years, synthetic 
procedures have been optimized to: (a) facilitate the 
incorporation of metals into the magnetic core that offer 
enhanced magnetic properties (e.g. zinc, cobalt, nickel), 
(b) coat with organic species (e.g. surfactants, polymers) 
to prevent degradation, and (c) deposit inorganic shell 
layers (e.g. silica, gold) for greater stability and additional 
surface functionalization [66].
The inherent magnetic properties of MNPs enable 
these particles to serve as useful multifunctional neu-
ral platforms. For instance, MNPs have been designed 
to selectively cross the BBB by minimizing the size and 
coating the surface with biocompatible polymer layers 
and chemical functionalities [67]. Further complexing 
with tumor-specific peptides (e.g. chlorotoxin, CTX) 
allowed the MNPs to be targeted to highly invasive gli-
oma brain tumors in mice models [67]. Moreover, this 
entire process could be monitored using MRI, making 
MNPs a versatile nanoparticle platform.
The high saturation magnetization properties of MNPs 
has also facilitated magnetic-based targeting. In this 
case, the dragging force of a permanent magnet is used 
to deliver MNPs to a target site. This has been demon-
strated for both in vitro gene delivery to neural stem cells 
[68] and in  vivo for drug/gene delivery to brain tumors 
of 9L-gliosarcoma-bearing rats [69]. Along with magnetic 
targeting, MNPs are becoming attractive for neuromodu-
lation as well. In one study, 30-nm CoFe2O4-BaTiO3 nan-
oparticles were injected through the mouse’s tail vein and 
forced to cross the BBB via a d.c. field, and then used to 
modulate the electric waveforms in the brain upon expo-
sure to an external a.c. field [70]. In another recent dem-
onstration, MNPs were even used to stimulate deep brain 
structures in  vivo through magnetic heating (Fig.  4a) 
[71]. The heat-sensitive capsaicin receptor TRPV1 was 
expressed with lentiviruses in the ventral tegmental area 
(VTA), followed by MNP injection into the same region. 
Subsequent exposure of the mice to alternating magnetic 
fields induced heat dissipation by hysteresis from the 
MNPs, permitting neuronal excitation by TRPV1-activa-
tion for up to one month after MNP injection (Fig. 4b). 
These diverse properties of MNPs offer unique applica-
tions for neural research.
3.1.4  Quantum dots
Quantum dots (QDs), also referred to as semiconductor 
nanocrystals, have emerged as an exciting class of fluo-
rescent probes. Conventional organic dyes readily pho-
tobleach upon prolonged irradiation, and tuning their 
optical properties is a general synthetic challenge [72]. In 
contrast, QDs are resistant to photobleaching, extremely 
bright, and exhibit size-dependent emission wavelengths. 
In particular, QDs tend to have a broad absorption spec-
trum and a narrow emission spectrum. This allows for 
the generation of QDs that can be excited with a single 
wavelength yet emit at different wavelengths [73]. Along 
with the small size range (~ 2-10 nm), this enables unique 
applications of QDs in multiplex imaging and biosensing.
Early on, a major limitation of QDs was the possibility 
of cytotoxic side effects. The most prominent QDs are 
composed of heavy metal ions, such as cadmium, sele-
nide and tellurium, which exhibit adverse effects upon 
exposure to cells and tissues [74]. Strategies have been 
devised to overcome these issues, which include coating 
the core QD with inert shells (e.g. ZnS, silica) to prevent 
leaching of toxic elements [75], or using biocompatible 
elements to generate non-toxic QDs (e.g. CuInS2, ZnS-
AgInS2) [76].
These synthetic optimizations have significantly 
improved QDs and made them attractive for neu-
roapplications. An early study used different surface 
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functionalization strategies to complex biomolecules like 
siRNA to QDs for the delivery into U87-glioblastoma 
brain tumor cells [77]. In such a case, the innate fluores-
cence property allows QDs to serve as a single vehicle for 
drug/biomolecule delivery, visualization and monitor-
ing. For instance, the QDs can be targeted to specific cell 
types to enable cellular tracking within the body. A recent 
study showed that the conjugation of QDs with cell-
penetrating lipopeptides and the subsequent injection 
into intact embryonic chick brains helped to identify and 
monitor neural stem cells as they migrate in the develop-
ing brain [78].
The long-term stability and robust fluorescence prop-
erties of QDs make them useful for mechanistic studies 
as well. For instance, the movement of QD-labeled nerve 
growth factor (NGF) was tracked in cultures of rat dorsal 
root ganglion (DRG) neurons to understand the mecha-
nism of retrograde axonal transport [79]. Preliminary 
studies have also exploited the optoelectronic proper-
ties of QDs to activate ion channels on neurons [80]. In 
this case, remote-controlled membrane depolarization 
or hyperpolarization was achieved in cortical neurons 
by activating K+ and Na+ channels using QD films and 
QD-coated micropipettes. The combination of the innate 
optical properties with the additional bioconjugation 
capabilities make QDs a favorable option for advanced 
studies.
Carbon-based quantum dots (CQDs or C-dots) have 
also recently emerged as a new category of fluorescent 
probes, with sizes below 10  nm. CQDs were first dis-
covered as a major impurity during the purification 
of single-walled carbon nanotubes using preparative 
electrophoresis [81]. Thereafter, a number of synthetic 
strategies were devised to generate CQDs, including 
electrochemical carbonization, laser ablation and hydro-
thermal treatment [82]. Compared to the traditional 
semiconductor-based quantum dots described above, 
CQDs have enhanced photoluminescence, solubility in 
water and biocompatibility [82]. These remarkable prop-
erties have made CQDs particularly useful for applica-
tions in bioimaging and biosensing [83]. In the context 
of neuroscience, CQDs were recently employed to tar-
get brain cancer glioma in mice [84]. Synthesized using 
a simple thermolysis route with d-glucose and l-aspar-
tic acid as starting materials, the as-prepared CQDs not 
only showed tunable emission spectra, but also intrinsic 
targeting to brain C6 glioma cells. While there are still 
limited investigations using CQDs for neuroapplications, 
such favorable properties makes this class of QDs attrac-
tive for future studies.
3.1.5  Upconversion nanoparticles
Upconversion nanoparticles (UCNPs) have attracted 
significant biomedical interest due to their ability to 
absorb low-energy photons and emit high-energy pho-
tons. In other words, UCNPs convert long-wavelength 
near-infrared light (NIR; >800  nm) to short-wavelength 
visible light (300–700  nm), known as an anti-Stokes 
process [85]. This phenomenon is possible due to the 
unique optical properties of the lanthanide-series ele-
ments, which are used as dopants within a crystalline 
host matrix, such as NaYF4 (Fig. 5a). Two different types 
of lanthanide-dopants are usually employed: a sensitizer 
and an activator. Upon NIR irradiation, the sensitizer 
(e.g. Yb3+) harvests NIR energy and transfers it through 
a non-radiative process to the activator (e.g. Er3+, Tm3+). 
Further transitions within the activator to higher energy 
levels then occur until radiative emission occurs [86].
Fig. 4 Magnetic Nanoparticles (MNPs). a Experimental scheme (left) showing magnetothermal deep brain stimulation using MNPs to open 
temperature-sensitive TRPV ion channels. Transmission electron microscopy image (right) showing the size and distribution of the MNPs. b Color 
maps of fluorescence intensity changes for TRPV1− and TRPV1+ cells before and during magnetic field exposure in the presence of MNPs. From 
Ref. [71]. Reprinted with permission from AAAS
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The ladder-like arrangements of energy levels in trivalent 
lanthanide ions (Ln3+) thus allows for visible light emis-
sions through various energy transfer pathways, depend-
ing on the pre-selected ion pairing [87]. As a result, while 
conventional organic dyes are sensitive to their chemical 
surroundings, the shielded 4f–4f intra-configurational 
transitions in UCNPs permit emissions that are independ-
ent of the particle size and environment [86]. The fixed 
energy levels, high resistance to photoblinking and pho-
tobleaching, long luminescence lifetimes (micro/milli-sec-
ond) and the upconversion process using deep-penetrating 
NIR light makes UCNPs ideal as in vivo probes [88].
UCNPs first emerged in neuroscience research for 
imaging and cancer application. In one study, the conju-
gation of the RGD peptide to the surface of NaYF4:Yb3+/
Tm3+ UCNPs allowed for targeted imaging of nude mice 
bearing human glioblastoma U87MG tumors [89]. Oth-
ers have conjugated neurotoxins such as chlorotoxin, 
which has the ability to target primary brain tumors, for 
imaging of xenograft glioma tumors in Balb-c nude mice 
in vivo and ex vivo [90]. In a recent study, a UCNP-based 
sensor was also designed for the detection of Zn2+ in 
brain slices from mice bearing Alzheimer’s disease [91].
The application of UCNPs has recently been extended 
to optogenetically modulate neuronal activity using near-
infrared light. Optogenetic approaches are contingent 
upon delivering a sufficient dose of visible light to the 
target opsin-expressing cells. Since visible light is highly 
scattered in tissue, invasive procedures are required to 
precisely implant optical fibers at the target site. In an 
alternative strategy, UCNPs have been shown for the first 
time to serve as mediators for converting deep-penetrat-
ing NIR light into visible light (e.g. blue light) to facili-
tate optogenetic neuronal control [92]. Embedding the 
UCNPs in a biodegradable polymer can further ensure 
a sufficient neural interface for repeated NIR-stimula-
tion (Fig. 5b). There is continued efforts to enhance the 
upconversion efficiency in order to improve UCNP-
based optogenetic control [93], as well as open new appli-
cations of UCNPs for neural research.
Fig. 5 Upconversion nanoparticles (UCNPs). a Schematic illustration (left) of UCNPs composed of a crystalline host and lanthanide dopant ions 
embedded in the host lattice. High-resolution transmission electron microscope image (center) revealing the single-crystalline nature of the crystal. 
Enlarged view (right) shows lanthanide (Ln) and sodium host (Na) atomic columns. Reproduced with permission from Ref. [87]. Copyright (2011), 
Nature Publishing Group. b Embedded within polymeric films, UCNPs can serve as internally excitable light sources that convert NIR light into blue 
light, thus facilitating optogenetic activation of channelrhodopsin (ChR)-expressing neurons. Reproduced form Ref. [92] with permission from The 
Royal Society of Chemistry
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3.2  Organic nanomaterials
The following organic nanomaterials will be discussed in 
this section: liposomes/micelles, dendrimers, polymeric 
NPs and carbon-based nanomaterials.
3.2.1  Liposomes/micelles
Amphiphiles, which contain both hydrophilic and hydro-
phobic domains, are powerful building blocks in biology 
[94]. They self-assemble in order to minimize the ener-
getically unfavorable interaction of hydrophobic moieties 
with the surrounding water molecules, leading to the for-
mation of well-defined nanoassemblies [95]. An example 
of this phenomena is the cellular membrane, which is the 
dynamic assembly of phospholipids. The chemical con-
trol of this assembly process has enabled the generation 
of various types of amphiphilic nanocarriers, in which 
liposomes and micelles are two well-known categories 
(Fig. 6a) [94].
Liposomes are spherical-shaped vesicles comprised 
of one or more vesicular bilayers (lamellae) [96]. This 
unique bilayer formation into a spherical assembly gen-
erally results in a core of aqueous solution, which can 
be loaded with hydrophilic compounds. At the same 
time, hydrophobic compounds can be loaded within the 
lipid bilayer itself. Liposomes are usually composed of 
natural phospholipids such as sphingomyelin and glyc-
erophospholipids, or synthetic polymers such as block 
copolymers [97]. Micelles, on the other hand, are spher-
ical-shaped assemblies that have a hydrophilic exterior 
and a hydrophobic interior [98]. In contrast to molecules 
Fig. 6 Liposomes and micelles. a Amphiphiles can assemble into liposomes (left), micelles (top) or lipid bilayers (bottom). Reproduced with permis-
sion from Ref. [95]. b Schematic (left) for preparation of siRNA-nanobubles (siRNA-NBs) using positively-charged siRNA micelles and gas-cored 
liposomes. Contrast enhanced ultrasound images on the right show the dispersion of siRNA-NBs and gas-cored liposomes (indicated by diminution 
in gray-scale intensity) upon low-frequency ultrasound exposure. Reprinted from Ref. [109]. Copyright (2013), with permission from Elsevier
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used to form liposomes, micelles consist of amphiphilic 
molecules (also known as surfactants) with one hydro-
phobic tail linked to one hydrophilic head. In turn, dis-
persion in water leads to the spontaneous formation 
of micelles, wherein the tail portion of the molecules 
sequester away from the water molecules into a highly 
hydrophobic core [99]. Pluronic block copolymers, such 
as ethylene oxide and propylene oxide, are wide-used for 
micelle formation [100].
Amphiphilic-based nanoassemblies like liposomes 
and micelles have been utilized for several decades now 
in neuroscience research, particularly for the gene/drug 
delivery to the CNS. Early work demonstrated lipo-
some-based drug vehicles capable of delivering antican-
cer agents like daunomycin across the BBB into the rat 
brain [101]. In such cases, modification with targeting 
moieties (e.g. antibodies) and stabilization with polyeth-
ylene glycol (PEG) conjugation to increase in vivo circu-
lation times proved to be essential. Recent studies have 
advanced the application of multifunctional liposomes to 
address a variety of neurological ailments in vivo, includ-
ing neuroprotection after cerebral ischemia [102], tar-
geting gliomas [103], treating brain metastasis [104] and 
reducing β-amyloid plaques in Alzheimer’s disease [105]. 
Polymeric micelles have been similarly applied. In one 
study, the cell-penetrating peptide TAT was anchored to 
micelles in order to deliver the antibiotic ciprofloxacin 
across the BBB to treat brain infections [106].
These amphiphilic nanoassemblies have also grown 
popular for other specialized neural applications. For 
example, liposomes have been used to mediate neural 
regeneration, wherein genes coding for neurotrophic 
growth factors (e.g. GDNF, NGF) were delivered after 
neuronal injury [107, 108]. The in  vivo expression of 
these growth factors was seen to promote axonal regen-
eration and improve locomotive function in adult rats 
[107]. Besides serving as a drug/gene carrier, liposomes 
and micelles have been uniquely used as externally-trig-
gerable agents. For example, a hetero-assembly of siRNA-
complexed polymeric micelles and gas-cored liposomes 
was recently synthesized to develop an ultrasound-based 
nanobubble therapy (Fig. 6b) [109]. In this case, the ultra-
sound-sensitive gas-cored liposomes carried the siRNA-
loaded micelles, resulting in enhanced delivery efficiency 
and gene silencing in a mouse glioma model. In general, 
the biocompatibility, facile surface functionalization, and 
lack of immune response have made these amphiphile-
based nanocarriers invaluable.
3.2.2  Dendrimers
Dendrimers are synthesized by the cross-linking of 
repeating monomer subunits [110]. This regular arrange-
ment of the monomers results in a highly-branched and 
well-defined hierarchical structure. Emanating from an 
initiator core, the layer-by-layer expansive growth allows 
for the synthesis of varying ‘generations’ of dendrimers 
with different hydrodynamic sizes, branching points and 
surface functionality (Fig. 7a) [111]. Further modification 
of the surface to introduce chemical functionalities (e.g. 
positive-charged amine groups) can render dendrim-
ers useful for complexation with drugs and gene vectors 
[112, 113]. Various types of dendrimer systems have been 
used for biological studies, including poly(propylene 
imine) (PPI) and poly(amidoamine) (PAMAM) [111].
Dendrimers are promising for targeted delivery to the 
brain. Attaching different classes of drugs for CNS thera-
pies, including anticancer, anti-inflammatory, and anti-
microbial agents, is facilitated by either encapsulation 
within the dendrimer or through chemical bonding [114]. 
Studies have shown the hydroxy-functionalized PAMAM 
dendrimers to be non-toxic, yet only minimal uptake was 
observed in both healthy and tumor-bearing animals 
[115]. However, enhanced PAMAM dendrimer uptake 
was observed into the brain following neuroinflamma-
tion, possibly due to impairment in the BBB [116]. The 
localization of dendrimers to activated microglia after 
systemic administration was observed in rabbit models 
of cerebral palsy, which in turn allowed for the targeted 
delivery of N-acetyl-l-cysteine (NAC), an antioxidant 
and anti-inflammatory agent [116]. Recent work further 
advanced these findings from the small animal rabbit 
injury model to a larger canine model [117]. After sys-
temic administration, PAMAM localized to the injured 
neurons and microglia in the brain of canines (Fig.  7b), 
allowing for the delivery of both NAC and valproic acid 
for enhanced neuroprotection [117]. Such seemingly 
inherent targeting, in addition to further modification 
of the dendrimer to incorporate therapeutics, makes the 
dendrimer class of nanomaterials clinically-relevant.
3.2.3  Polymeric nanoparticles
Polymeric nanoparticles are composed of natural or syn-
thetic polymers, and are generally biodegradable. Exam-
ples of synthetic polymer-based nanoparticles include 
poly(lactide-co-glycolide) (PLGA), poly(butylcyano-
acrylate) (PBCA), poly(glycolic acid) (PGA) and 
poly(lactic acid) (PLA), and natural polymers include 
alginate, collagen and gelatin [118]. Ranging in size from 
10  nm to upwards of several micrometers, these carri-
ers can be formed into solid nanospheres (matrix-based) 
or nanocapsules (liquid core surrounded by polymer 
shell). These carriers can further contain therapeutics by: 
(a) dissolving, absorbing or dispersing throughout the 
matrix; (b) covalent attachment to the polymer matrix; or 
(c) encapsulation within the core [119]. The key advan-
tage of using a polymeric-based particle is that it provides 
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a protective coating for the therapeutic, which ensures 
enhanced stability and efficacy after in  vivo adminis-
tration compared to the free form [119]. Moreover, the 
pharmacokinetic properties of the therapeutic-loaded 
polymeric nanoparticles can be further enhanced by 
functionalizing the surface, which can enable targeted 
delivery as well as increased permeability through the 
BBB [120].
The CNS delivery of drugs or biomolecules is a key 
application of polymeric nanoparticles. Early studies 
found PBCA nanoparticles to be effective for CNS deliv-
ery. In one study, the antinociceptive opioid hexapeptide 
dalargin was transported across the BBB, which oth-
erwise could not enter the brain in sufficient quantities 
to induce antinociception [121]. Follow-up studies also 
showed the BBB translocation of such acrylate-based 
particles by surface conjugation of apolipoproteins [122]. 
Nonetheless, the rapid degradation of PBCA serves to 
minimize cytotoxicity resulting from polymer accumula-
tion, and further permits the delivery of a variety of drugs 
Fig. 7 Dendrimers. a Schematic 2D representation (left) of a dendrimer containing three generations (branching points) as indicated by numbers. A 
3D representation (right) of dendrimer G3 showing space-filling structure. Reprinted form Ref. [111]. Copyright (2009), with permission from Elsevier. 
b Systemically administered dendrimer-FITC (D-FITC) localize in the injured brain. D-FITC was administered IV after 2 h hypothermic circulatory 
arrest (HCA) or cardiopulmonary bypass (CPB); fluorescent labeling was examined 48 h later. D-FITC labeling in the outer part of the hippocampal 
dentate granule cell layer (dgc) after HCA closely corresponds to the distribution of apoptotic nuclei detected with DAPI (top). Negligible labeling 
is observed in the hippocampus after CPB, which causes little to no injury (bottom). In cerebellum after HCA, D-FITC is prominent in many Purkinje 
cells (PC), which receive dense glutamatergic input and are often injured, and surrounding small hemorrhages (*). Reproduced with permission 
from Ref. [117]. Copyright (2014) American Chemical Society
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to the CNS, including doxorubicin, methotrexate, lopera-
mide and temozolomide [123].
Polyester-based nanoparticles like PLGA have been 
observed to be safer alternatives for brain delivery since 
the degradation products are mainly water and carbon 
dioxide [124]. Besides drugs, polymeric nanoparticles 
have been useful for the sustained release of growth fac-
tors to treat neurodegenerative disorders. In a Hunting-
ton’s disease rat model, the local administration of nerve 
growth factor (NGF)-loaded PLGA enabled neuropro-
tection after excitotoxin quinolinic acid injections [125]. 
Similar loading with other tropic factors and neurotrans-
mitters has led to significant results for neuroprotection 
and repair [18, 126]. Polymeric nanoparticles have also 
been used to direct neural stem cell behavior in vivo. For 
example, PEI-based nanoparticles were complexed with 
retinoic acid to control neural differentiation in the sub-
ventricular zone (neural stem cell niche) [127] and after 
ischemia [128]. In this way, polymeric nanoparticles will 
continue to provide utility in advancing studies.
3.2.4  Carbon‑based nanomaterials
Carbon-based nanomaterials are becoming attractive due 
to their unique optical, thermal, mechanical, electrical 
and chemical properties. Composed of sp2-bonded gra-
phitic carbon, these nanomaterials are categorized into 
zero-dimensional, one-dimensional and two-dimensional 
structures (Fig. 8a) [129]. Laser ablation of graphite was 
used to isolate the well-known C60 buckyball in 1985, a 
zero-dimensional fullerene derivative, which was the 
first carbon nanomaterial to be isolated [130]. Soon after, 
one-dimensional carbon nanotubes (CNTs) were pre-
pared using arc discharge techniques in 1991 [131]. The 
cylindrical carbon structure has an extended sp2 carbon 
with physical properties that can be tuned, such as the 
diameter, length, number of walls/cylindrical layers and 
chirality [132]. CNTs are in fact made of graphene sheets 
wrapped onto themselves, but two-dimensional graphene 
was not isolated until 2004, using mechanical exfoliation 
[133]. As a single-atom thick sheet, graphene exhibits a 
number of remarkable properties, including: high planar 
surface area, superior mechanical strength, unparalleled 
thermal conductivity, and favorable electronic properties 
and optical properties [134]. Further modifications to the 
graphene surface, like oxidation to create graphene oxide, 
has resulted in derivatives with complementary proper-
ties for biological studies (e.g. enhanced water solubility, 
facile functionalization for biomolecule conjugation, etc.) 
[135].
Besides serving as a remarkable material for the bio-
medical field in general, carbon-based nanomateri-
als have become especially useful in neuroengineering, 
where the focus is the development of devices or surfaces 
to effectively interface with the CNS [136]. The first 
report using these materials for neural research was the 
growth of embryonic rat brain neurons on multi-walled 
CNTs (Fig.  8b) [137]. This early work highlighted the 
importance of modifying the CNT surface for enhanced 
neurite outgrowth, a critical feature for enhanced in vivo 
performance in terms of biocompatibility, neuron growth 
and neurite/axonal elongation. While graphene is similar 
to CNTs in many ways, the two-dimensional structure 
and flexibility of graphene allows for facile coating on 
numerous types of cell culture surfaces. The early dem-
onstration of the biocompatible interaction of neurons 
with graphene showed favorable long-term outcomes, in 
which mouse hippocampal neurons had enhanced neu-
rite sprouting and outgrowth on graphene-coated tissue 
culture polystyrene (TCPS) compared to bare TCPS sub-
strates [138].
The promising results from neuronal cultures led to the 
examination of carbon-based nanomaterials for stem cell 
cultures. One of the earliest studies showed the success-
ful differentiation of mouse NSCs on single-walled CNT-
polyelectrolyte multilayer thin films into neural cells 
[139]. The viability, neurite outgrowth and neural marker 
expression was found to be comparable between the con-
ventional poly-l-ornithine (PLO) surface and the CNT 
surface. Further modifications of CNTs has also resulted 
in enhanced neuronal differentiation, both by using dif-
ferent types of stem cells, like hESCs [140] and hMSCs 
[141], and by combining with other biomaterials, like col-
lagen [142] and silk [143]. Graphene-coated surfaces have 
also shown similar enhancements in neuronal formation 
[144], axonal alignment [145], neuronal patterning [146] 
and oligodendrocyte differentiation [147] (Fig. 8c, d).
An exceptional feature of carbon-based nanomate-
rial for neural research is its inherent electrical proper-
ties [148]. For example, the large electrical conductivity 
originating from the highly-mobile π-electrons has been 
seen to influence neurite outgrowth of dissociated hip-
pocampal neurons grown on single-walled CNT films 
[149]. Combining graphene with polyethylene tereph-
thalate (PET), the hybrid was shown to act as an electri-
cal stimulator, in which electric field stimulation caused 
increased cell-to-cell couplings in a human neuroblas-
toma cell line [150]. Interestingly, this electrical field 
stimulation was achieved in a non-contact manner, and 
was non-cytotoxic. Implanting electrodes coated with 
carbon nanomaterials has also shown great promise. In 
one study, CNT coating on conventional tungsten and 
stainless steel wire electrodes was seen to decrease elec-
trode impedance and increase charge transfer, permitting 
both enhanced recording and electrical stimulation in rat 
and monkey brains [151]. Recently, graphene-coating of 
microelectrode arrays has even enabled in vivo imaging, 
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Fig. 8 Carbon-based nanomaterials. a Carbon nanomaterials include zero-dimensional fullerenes, one-dimensional carbon nanotubes (CNTs), and 
two-dimensional graphene. Reproduced with permission from Ref. [129]. b Scanning electron microscopy image of embryonic hippocampal neu-
rons growing on dispersed multiwall CNTs. Reproduced with permission from [137]. Copyright (2000), Springer. c Adipose-derived stem cells grown 
on graphene patterns show enhanced differentiation into neuronal cell fate. Reprinted with permission from Ref. [146]. Copyright (2015) American 
Chemical Society. d Graphene-coating on polymeric nanofibers promoted the selective differentiation of neural stem cells into oligodendrocytes. 
Reproduced with permission from Ref. [147]. Copyright 2014, WILEY–VCH Verlag GmbH & Co. KGaA, Weinheim. e Diagram (left) of graphene-based 
carbon-layered electrode array device construction showing the layered structures. Demonstration of the flexibility of the device (center) by wrap-
ping around a glass bar with a radius of 2.9 mm. Bright-field image (right, top) and fluorescence image (right, bottom) of the device implanted on 
the cerebral cortex of a mouse beneath a cranial window. Green labelling indicates the vasculature. Reproduced with permission from Ref. [152]. 
Copyright (2014), Nature Publishing Group
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neurophysiological recording and optogenetic activa-
tion in the rodent brain (Fig. 8e) [152]. Considering these 
exceptional features, carbon-based nanomaterials have 
great promise for improving neural interfaces. With more 
and more studies verifying the compatibility of such 
materials, there is immense scope for using these robust 
materials in translational studies.
4  Conclusions
From both a fundamental and an applied science point-
of-view, nanotechnology and nanoscience has greatly 
advanced in a relatively short period of time. Nanomedi-
cine in particular has seen a steady progress in the last 
two decades, with tremendous efforts being placed in 
translating these advances to the field of neuroscience. A 
wide array of nanomaterials show promise for enhancing 
our understanding of the CNS, moreover offering thera-
peutic opportunities in CNS-related treatment. Many 
of the inorganic-based nanomaterials, such as metal-
lic nanoparticles, magnetic nanoparticles and quantum 
dots, are being extensively employed as imaging agents. 
Other inorganic nanomaterials provide unique advan-
tages, such as enhanced small molecule/biomolecule 
loading with silica nanoparticles and improved optical 
penetration with upconversion nanoparticles. This makes 
them quite versatile and adaptable to crucial neuroappli-
cations such as CNS drug delivery and deep tissue imag-
ing, respectively. In contrast, organic nanomaterials such 
as micelles, liposomes dendrimers and polymeric nano-
particles are generally biocompatible and biodegradable 
right from the start. In addition, carbon-based nanoma-
terials offer superior material properties, making this 
class of nanomaterials attractive candidates for neural 
interfaces. The availability of such a diverse nano-toolkit 
has changed the way scientists approach challenges in 
neuroscience.
Nevertheless, a growing need exists to create nano-
based platforms that bear multiple functionalities on 
a single platform. This is mainly due to highly complex 
nature of the CNS, and furthermore it’s sensitivity to 
slight damage and the consequent limited capability for 
autonomous repair. As a result, approaches that enable 
maximal effectiveness with minimal perturbation of 
the intact tissue would be ideal. In developing the next 
generation of nanoscale CNS platforms, critical design 
criteria consist of: attachment of multiple types of thera-
peutic agents, spatiotemporal control within the body, 
built-in modalities for long-term tracking, and capabili-
ties to record and modulate neural activity. Integrating 
these features on a single nanoplatform holds remark-
able potential for utilizing the nanomaterial toolkit for 
advanced neuroengineering applications.
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